The Association Between Drug Approvals and Burden of Disease From 1990 to 2017

Affiliations

¹ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
² Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. jballre2@jhu.edu.
³ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Tarun George et al. J Gen Intern Med. 2021 Nov.

. 2021 Nov;36(11):3615-3617.

doi: 10.1007/s11606-020-06525-3. Epub 2021 Feb 2.

¹ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
² Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. jballre2@jhu.edu.
³ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

No abstract available

Conflict of interest statement

The authors declare that they do not have a conflict of interest.

1. Research C for DE and. Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals. FDA [Internet]. 2020 Feb 21 [cited 2020 Jul 29]; Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-...
1. Global Burden of Disease Study 2017. Institute for Health Metrics and Evaluation (IHME). 2018.
1. Cleary EG, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010–2016. Proceedings of the National Academy of Sciences. 2018;115(10):2329–2334. doi: 10.1073/pnas.1715368115. - DOI - PMC - PubMed